Emergency
+91 9924023456
+91 9904722345
+91 9913460101
+91 9824344554

Investor Relations

Home » Investors

SHALBY INVESTOR RELATIONS


Shalby Limited (NSE: SHALBY) and Stock Exchange Information (BSE: 540797) is India’s leading multi-specialty hospital operating a chain of 11 tertiary hospitals with an aggregate bed capacity of over 2,000 hospital beds. It is one of the top hospitals in joint replacement surgery in India. Shalby is the number one player worldwide for knee replacement surgery and has a 4,000 plus in-house team of skilled doctors, surgeons and support staff. The objective of the Investor Relation Website is to ensure continuous and open communication with its shareholders and all financial market participants.

Registered Office
Name Shalby Limited
Address Opp. Karnawati Club,Sarkhej Gandhinagar Highway,Near Prahlad Nagar Garden,Ahmedabad – 380 015, Gujarat, India
Phone  +91 79 4020 3000
Fax +91 79 4020 3120
CIN L85110GJ2004PLC044667
Grievance Redressal & Nodal Officer
Name Mr. Tushar Shah (Associate Vice President and Company Secretary)
Email Companysecretary@shalby.in
Phone +91 79 4020 3000 / +91 79 40203296
Online Dispute Resolution ODR
Investor Relations
Name Mr. Puneet Maheshwari
Email ircs3.corp@shalby.org
Phone +91 9512049871
Registrar & Transfer Agent
Name KFIN Technologies Limited
Address Selenium Building, Tower-B,
Plot No 31 & 32,Financial District,
Nanakramguda, Serilingampally,
Hyderabad, Rangareddy,
Telangana India - 500 032.
Email einward.ris@kfintech.com
Phone 1800 309 4001
WhatsApp +91 910 009 4099
KPRISM
KFIN Corporate Website Link
Corporate Registry (RIS) Website Link
Investor Support Centre Link

Investors

For Investors holding shares in Physical mode

If you have any dispute against a listed company and or its Registrar and Share Transfer Agent (RTA) on delay or default in processing your request, as per SEBI circular dated 30.05.2022 , you can file for arbitration with Stock Exchange.

For more details, please see the web links of the stock exchanges
BSE - http://tiny.cc/m1l2vz
NSE - http://tiny.cc/s1l2vz

Annual Reports
2022-23 2021-22 2020-21 2019-20 2018-19 2017-18 2016-17
Shalby Limited
Subsidiary Companies
Shalby (Kenya) Limited
Yogeshwar Healthcare Ltd.
Vrundavan Shalby Hospitals Ltd.
Shalby International Ltd.
Griffin Mediquip LLP
Slaney Healthcare
Mars Medical Devices
Shalby Hospital Mumbai Pvt Limited
Annual Return
FY 2022-23
FY 2021-22
FY 2020-21
FY 2019-20
FY 2018-19
FY 2017-18
Financial Year Q1 Q2 Q3 Q4
2023-24
2022-23
2021-22
2020-21
2019-20
2018-19
2017-18

 

Financial Year Q1 Q2 Q3 Q4
2023-24
2022-23
2021-22
2020-21
2019-20
2018-19
2017-18

 

Investor Presentation June-21

Financial Year Q1 Q2 Q3 Q4
2023-24
2022-23
2021-22
2020-21
2019-20
2018-19

 

Financial Year Q1 Q2 Q3 Q4
2023-24
2022-23
2021-22
2020-21
Financial Year Q1 Q2 Q3 Q4
2023-24
2022-23
2021-22
2020-21
2019-20
2018-19
2017-18  

Completion of Acquisition of 100% Equity Stake in Healers Hospital Pvt. Ltd
Availing Term Loan of Rs. 100 crore from Bajaj Finance Ltd for acquisition of 100% stake in Healers Hospital
Acquisition of 100% equity stake in Healers Hospital Pvt. Ltd.
Disclosure under Reg 7(2) of SEBI (PIT) Reg, 2015 – 07-03-2024
Disclosure under Reg 29(2) of SEBI (SAST) Reg, 2011 – 07-03-2024
Notice to MMDL from Customs Dept
Recording of Conference call – 12-02-2024
Grant of ESOP
Concall Invite Q3 FY 2023-24
Change in Senior Management - Resignation of Chief Business Officer
Closure of Corporate Guarantee
 PK Healthcare Pvt. Ltd. become subsidiary of Shalby Ltd.
 Exercise of Stock Options under Shalby Limited Employees Stock Options Scheme - 2021
 Acquisition of 87.26% stake in PK Healthcare Pvt. Ltd. (Sanar International Hospitals)
 Dr. Vikram Shah, CMD awarded with Prestigious Healthcare Entrepreneur Award by Hurun
Shalby Academy – Signing of MoU with Kaushalya, Skill University of the Government of Gujarat, at Vibrant Gujarat Global Summit 2024
  Appointment of Global Chief Business Officer
  Reaffirmation and Assignment of Credit Rating
  Reconciliation of Share Capital Audit Report Q3 FY 2023-24
  Certificate ur. 74(5) – Q3 FY 2023-24
  Closure of Trading Window for Q3 FY 2023-24
  Further Investment by MMDL in SGTPL (December 2023)
  Availing enhanced SBLC facilities
  Investor Meet on 06-12-2023
  Exercise of Stock Options under Shalby Limited Employees Stock Options Scheme - 2021
  Investor Meet 05-12-2023 at Singapore
  Participating in Road Show at Singapore on 04-12-2023
  Intimation of Change in Senior Management
  Execution of Amendment Agreement with BCJ Hospital (Santacruz)
  Recording of Conference call – 30-10-2023
  Healthcare Personality of the Year Award 2023 (FICCI) to Our CMD, Dr. Vikram Shah
  Grant of ESOP
  Concall Invite Q2 FY 2023-24
  Update On Pending Material Litigation - Order Passed By Statutory Authority
  Reconciliation of Share Capital Audit Report Q2 FY 2023-24
  Certificate ur. 74(5) – Q2 FY 2023-24
  Intimation to investors on Online Dispute Resolution (ODR) Mechanism
  Closure of Trading Window for Q2 FY 2023-24
  Further Investment by MMDL in SGTPL (Sept 2023)
  Allotment of Preference Shares by MMDL to Shalby
  Analyst Meet with New Varnon Capital
  Signing of MoU with Sardar Vallabhbhai Global University by Shalby Academy (a Unit of Shalby Ltd.)
  Investment by Mars Medical Devices Limited in its subsidiary (SAT) by way of Preference Stock
  Secretarial Compliance
  Clarification to NSE for delay in disclosure of Transcript of Earning Conference Call
  Clarification to NSE for spurt in volume
  Clarification to BSE for spurt in volume
  Agreement for SOCE-Ranchi
  Participation in Conference call – IIFL Securities
  Closure of Trading Window for Q1 FY 2023-24
  Certificate ur. 74(5) – Q1 FY 2023-24
  Reconciliation of Share Capital Audit Report Q1 FY 2023-24
  Grant of ESOP
  Concall Invite Q1 FY 2023-24
  Clarification to NSE regarding Corporate Governance Report Q1 FY2023-24
  Clarification to BSE regarding Shareholding Pattern Q1 FY2023-24
  Analyst Meet with Motilal Oswal Asset Management
  Inauguration of Hospital at Ranchi
  Disclosure - Details of Pending Material Litigation(s) / Disputes
  Clarification to BSE regarding Corporate Governance Report Q1 FY2023-24
 Investor / Analyst Meet – 05-09-2023
 Clarification to NSE for spurt in volume
 Signing of MoU with P P Savani University by Shalby Academy
 Intimation to Shareholders for updation of KYC/PAN/Nomination
 Initial disclosure on large corporates
  Reappointment of Auditors for Second term
  Change in policy on criteria for determining materiality of events
  Change in KMP
  Appointment of Independent Director
  Dividend announcement

 Concall Invite Q4 FY 2022-23
 concall recording Q4 FY2022-23
 Concall Invite Q4 FY2023
 Outcome of Board Meeting for year ended March 31, 2023
 Certificate under 40(10)
 Reconciliation of Share Capital Audit Report Q4 FY 2022-23
 Certificate ur. 74(5) – Q4 FY 2023
 Certificate ur. 7(3) - FY 2023
 Closure of Trading Window for Q4 FY 2022-23
 Allotment of Preference Shares to Shalby Ltd by Mars Medical Devices Limited
 Further Investment by MMDL in SGTPL (Mar 2023)
 Signing of MOU with Silver Oak University by Shalby Academy.
 Schedule of Investor Meet (Feb 2023)
 Receipt of Import License by Step-down subsidiary – Shalby Global Technologies Pte. Ltd., Singapore
 Signing of MOU with IIPH Gandhinagar by Shalby Academy
 Schedule of Investor / Analyst meet
 Update On Vrundavan Shalby Hospitals Limited - Wholly Owned Subsidiary
 Inauguration of Shalby Orthopedics Centre of Excellence (SOCE) at Gwalior
 Reconciliation of Share Capital Audit report Q3 FY 2022-23.
 93ScheduleConcall as Concall Invite Q3 FY 2023
 94Reg745 as Certificate ur. 74(5) – Q3 FY 2023
 Closure of Trading Window for Q3 FY2023
 Allotment to Shalby Ltd by Vrundavan Shalby Hospitals Ltd.
 Reaffirmation of Credit Rating
 Conversion of Loan of MMDL to SAT into Preferred Stock and Common Stock
 Schedule of Investor Meet ( Dec 2022)
 Shalby Issued SBLC Amounting To USD 9.45 Million For Shalby Advanced Technologies, Inc. USA
 Disclosure under Reg 29(2) of SEBI (SAST) Reg, 2011 – 07-12-2022
 Disclosure under Reg 7(2) of SEBI (PIT) Reg, 2015 – 07-12-2022
 Further Investment by MMDL in SGTPL (Dec 2022)
 Demise of Mr. Kiritbhai Chimanlal Shah, Promoter Group
 Disclosure under Reg 29(2) of SEBI (SAST) Reg, 2011 – 29-11-2022
 Disclosure under Reg 7(2) of SEBI (PIT) Reg, 2015 – 29-11-2022
 Disclosure under Reg 29(2) of SEBI (SAST) Reg, 2011 – 17-11-2022
 Disclosure under Reg 7(2) of SEBI (PIT) Reg, 2015 – 17-11-2022
 Grant of ESOPs
 Newspaper Ad – Postal Ballot 2022
 Disclosure under Reg 7(2) of SEBI (PIT) Reg, 2015
 Disclosure under Reg 29(2) of SEBI (SAST) Reg, 2011
 Appointment of Mr. Parag Agarawal as Chief Business Officer
 Calendar of Events for Postal Ballot Process.
 Newspaper Advertisement for Q2 FY2023 Results
 Initial Disclosure under SEBI(PIT) Reg, by Mr. Vijay Kedia, director
 Appointment of Mr. Vijay Kedia as Additional Director (Non-Executive Non Independent).
 Re-appointment of Mrs. Sujana Shah as an Independent Director for second term w.e.f. 7th May 2023.
 Reconciliation of Share Capital Audit report
 Grant of Options under ESOP Scheme 2021 (Oct 2022)
 Concall Invite Q2 FY 2023
 Certificate ur. 74(5) – Q2 FY 2023
 Allotment of Equity & Preference Shares by MMDL to Shalby
 Closure of Trading Window Q2 FY2023
 Further Investment by MMDL in SGTPL (Aug 2022)
 Terms of Grant of Options
 Shalby Enters into Partnership with Australian Health Ed-Tech Company
 Concall Invite Q1 FY 2023
 Reconciliation of Share Capital Audit Report Q1 FY 2023
 Certificate ur. 74(5) – Q1 FY 2023
 Grant of Options under ESOP Scheme 2021 (Jul 2022)
 Disclosure under SEBI (SAST) Regulations, 2011 (14 Jun 2022)
 SEBI (Prohibition of Insider Trading) Reg.2015 (14 Jun 2022)
 Grant of Options under ESOP Scheme 2021 (Jun 2022)
 Disclosure under SEBI (SAST) Regulations, 2011 (Jun 2022)
 SEBI (Prohibition of Insider Trading) Reg. 2015 (Jun 2022)
 Acq. of Shares by Shalby Employees Welfare Trust (May 2022)
 Grant of Options Under ESOP Scheme 2021 (May 2022)

 Concall Invite Q4 FY2022
 Annual Secretarial Compliance Report FY2022
 Newspaper Advertisement for Q4 FY2022 Results
 Certificate under Reg. 40(10) of SEBI (LODR) – FY 2022
 Disclosure of Large Corporate (Apr 2022)
 Reconciliation of Share Capital Audit Report Q4 FY 2022
 Certificate ur. 74(5) – Q4 FY 2022
 Certificate ur. 7(3) - FY 2022
 Further Investment by MMDL in SGTPL (Mar 2022)
 Change in Name of Registrar & Transfer Agent (Mar 2022)
 Schedule of Investor-Analyst Meet (Mar 2022)
 Schedule of Group Investor-Analyst Meet (Mar 2022)
 Inauguration of SOCE in Ahmedabad (Mar 2022)
 Receipt of Import License to Subsidiary - MMDL (Feb 2022)
 Schedule of Investor-Analyst Meet Q3 FY2022
 Determining Materiality of an Event/Info by KMPs(Feb 2022)
 Appointment of Chief Financial Officer (Feb 2022)
 Further Investment by MMDL in SAT (Jan 2022)
 Certificate Under Reg. 74(5) Q3 FY 2022
 Reconciliation of Share Capital Audit Report Q3 FY 2022
 Resignation of Chief Financial Officer (Dec 2021)
 Further investment by MMDL in SGTPL (Dec 2021)
 Schedule of Investor-Analyst Meet (Nov 2021)
 Long Term Credit Rating for Enhanced Rated Amount (Nov 2021)
 Newspaper Advertisement for Q2 FY2022 Results
 Schedule of Investor-Analyst Meet Q2 FY2022
 Reconciliation of Share Capital Audit Report Q2 FY2022
 Upgradation of Credit Rating (Sep 2021)
 Revised Conference Call Invite (Aug 2021)
 Conference Call Invite (Aug 2021)
 Mars Medical Acquires 96% Shares in Shalby Global (Jul 2021)
 Reconciliation of Share Capital Audit Report Q1 FY2022
 Certificate Under Reg. 74(5) (Jun 2021)
 Reg. 30 of SEBl (LODR)- Inaugurated Shalby Zynova (Jun 2021)
 Conference Call Invite & Investor Presentation (May 2021)
 Appointment of Vice Chairman & Global President (May 2021)
 Concall Invite for Audited Financials-Q4 & FY2021 (May 2021)
 Step-down Subsidiary in USA (May 2021)
 Newspaper Publication - Offer for Sale (Apr 2021)
 Disclosure of Large Corporate (Apr 2021)

 Intimation Of Subsidiary Company
 Con-call with Investors to address general queries about ongoing COVID-19 pandamic
 Con-call with Investors hosted by HDFS Sec to address general queries about ongoing COVID-19 pandemic
 Clarification Of Price MOvement To NSE
 Clarification Of Price MOvement To BSE
 Intimation of Testing of COVID-19 cases at Indore Shalby Hospital
 Con-call intimation hosted by Edelweiss
 Con-call intimation hosted by Edelweiss
 Compliance Certificate 7(3) – 31-03-2020
 Certificate under Reg.74(5) of SEBI (DP) Regulations, 2018
  Treatment of Covid-19 Patient at Shalby Hospital
 Conference call hosted by Centrum Broking Ltd.
 Certificate under Regulation 40(10) of SEBI LODR –H1 FY 2019-20
 Reconciliation of Share Capital Audit Report Q4 FY 2019-20
 Disclosure as to Large Corporate
 Schedule of Investor / Analyst Meet Q4 FY20
 Trading Window Closure Notice For Q1 FY2021
 Intimation of Treatment of Covid-19 Patient at Shalby Hospital, Surat
 Intimation of Treatment of Covid-19 Patient at Shalby Hospital, Vapi
 Credit Rating ICRA Reg 30 LODR
 Certificate under Regulation 74 (5) Q1 2020-21
 Disclosure of impact of CoVID-19 on the business and operations
 Reconciliation of Share Capital Audit Report Q1 FY 2020-21
 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome”
 Announcement under Secretarial Compliance Report FY 2019-20”
 Aquisition Subsidiaries
 Investor Call Intimation
 Submission of newspaper ad for results Q1 FY2020-21
 Notice of 16th Annual General Meeting
 Intimation of Board of Directors Meeting
 Outcome of Board meeting
 Compliance Certificate 7(3) – 30-09-2020
 Certificate under Regulation 74 (5) Q2 2020-21
 Investor Conference Call Q2 F.Y. 2020-21
 Newspaper Ad for Results Q2 FY 2020-21
 Certificate under Regulation 40(10) of SEBI LODR –H1 FY 2020-21
 Reconciliation of Share Capital Audit Report Q2 FY 2020-21
 Investor Analyst Call
 Intimation Of Subsidiary Company SHMPL
 Intimation Of Subsidiary Company SHMPL
 Certificate under Regulation 74 (5) Q3 2020-21
 Schedule of Investor / Analyst Meet Q3 FY2021
 Shalby Limited Q3 FY2021 Press Release
 Reconciliation of Share Capital Audit Report Q3 FY 2020-21
 Investor / Analyst Meet
Change in Company Secretary & Compliance Officer
Disclosure under Regulation 30 (5) of the SEBl - LODR
Annual Secretarial Compliance Report FY2021
Reconciliation of Share Capital Audit Report Q4 FY2021

Intimation of Trading Window Closure
Compliance Certificate 7(3)-31-03-2019
 Intimation Of Analyst Meet
 Certificate under Regulation 40(10) of SEBI LODR –H2 FY 2018-19
 Reconciliation of Share Capital Q4 2018-19
 Interaction with electronic media
 Recommendation of Dividend for FY 2018-19
 Schedule of Investor / Analyst Meet Q4 FY19
 Submission of newspaper ad results Q4 FY2018-19
 Disclosure under SEBI PIT Reg. 7(2) 30.05.2019
 Disclosure under SEBI PIT Reg. 7(2) 01.06.2019
 Intimation of Trading Window Closure
 Best IT enabled Hospital Award
 Reconciliation of Share Capital Q1 2019-20
 Certificate under Regulation 74 (5) Q1 2019-20
 Schedule of Investor Conference Call Q1 FY19
 News Paper Advertisement PAS-1 AGM
 Participation in Emkay Confluence at Mumbai – 08-Aug-2019
 Participation in Elara Annual Conference at Mumbai-– 05-September-2019
 Gujarat HealthCare Leadership Award 2019
 Intimation of Trading Window closure – Q2 FY 2019-20 Fin. Results
 Dare to Dream -Zee Business Award - Company of the Year
 Credit Rating ICRA Reg 30 LODR
 Certificate under Regulation 40(10) of SEBI LODR –H1 FY 2019-20
 Clarification Of Price Movement
 Investor Con-call Q2 FY2019-20
 Press Release- Q2FY20 Financial Results
 Submission of newspaper ad results Q2 FY2019-20
 Change of name of Registrar & Transfer Agent
Intimation of Trading Window closure – Q3 FY 2019-20 Fin. Results
 Compliance Certificate Q3 30-09-2019
 Reconciliation of Share Capital Audit Report Q3 FY 2019-20
 Change in Details of RTA
 Investor Con-call Q3 FY2019-20
 Clarification as to increase in volume of shares
 Re-appointment of CMD
 Submission of newspaper ad results Q3 FY2019-20
 Disclosure under SEBI PIT Reg. 7(2) 26.02.2020

Statement of Investor Complaints – Q4 FY 2017-18
Share Capital Audit – 31-03-2018
Compliance Certificate under Reg. 7(3) of LODR
Press Release – MoU with Sen Sok Intl Hospital, Cambodia
Certificate under Regulation 40(10) of SEBI LODR
Joint Replacement Surgeries under Mukhyamantri Amrutam Yojana
Change in CIN
Schedule of Investor / Analyst Meet
Schedule of Investor / Analyst Meet – 27-04-2018
Intimation Conference Call
Intimation Appointment of CDSL as designated depository
Collaboration with Berkeley Health Education
Investor/Analyst meeting with Motilal Oswal Securities Limited
Investors meet/UBS India- Midcap conference
Resignation of Chief Executive Officer of the Company
Intimation Analyst meet HDFC Securities 26-06-2018
Updates relating to resignation of CEO
Man of the Year Award – Dr. Vikram Shah
Intimation Analyst meet – 26-06-2018
Intimation Analyst meet - 27-06-2018
Intimation Analyst meet - 02-07-2018
Intimation Analyst meet – 06-07-2018
Intimation Liver Disease and Transplantation
Karvy Reconciliation Report
Investor Grievance report
 Intimation of AGM
 Intimation of Book closure
 AGM Notice & Annual Report 2017-18
 Newspaper Ad. AGM, Book closure & E-voting
 Outcome of AGM
 Voting Results
 Shalby Press Release - Ovarian Mass Removal Jaipur
 Credit Rating ICRA Reg 30 LODR
 Reg 30 Orthotrends 2018 Chandigarh
 Intimation under Regulation 30 of SEBI LODR-concall with Edelweiss
 Investor Grievance Report Q2 FY 2018-19
 Share Capital Audit Q2 FY 2018-19
 Compliance Certificate 7(3) – 30-09-2018
 Certificate under Regulation 40(10) of SEBI LODR –H1 FY 2018-19
 Pre Accreditation Entry level NABH at Shalby Surat
 Intimation for Conference call
 Submission of newspaper AD – Notice of Board Meeting
 Pre-Accreditation Entry level NABH at Shalby Naroda
 Newspaper ad for Issue of Duplicate Shares
 Intimation Analyst Meet – Nalanda Capital
 Intimation participation in IDFC Investor Conference
 Investor conference Kotak
 Intimation Issue of Duplicate Shares
 Press Release Kolkata
 Intimation Transfer of operations Karvy
 Medical Value Travel Specialist Hospital Award 2018
 Best hospital for Medical Tourism in Gujarat Award
 Share Capital Audit Q3 FY 2018-19
  Intimation of Investor Analyst Concall
Intimation of Conference Call
Intimation Analyst meet - DSP BlackRock Investment
 Newspaper ad for Q3 FY 2018-19 Results

Financial Year Q1 Q2 Q3 Q4
2023-24
2022-23
2021-22
2020-21
2019-20
2018-19
2017-18
Financial Year Q1 Q2 Q3 Q4
Board Meeting Intimation News Paper Ad. Intimation News Paper Ad. Intimation News Paper Ad. Intimation News Paper Ad.
2023-24
2022-23
2021-22
2020-21
2019-20
2018-19
2017-18

 

Share Holder’s Meeting

General Meeting Intimation Book closure / Record date Advertisement Outcome Voting Result
19th AGM – 14-08-2023
Postal Ballot Notice dated 18-10-2022
18th AGM – 26-09-2022
Postal Ballot Notice dated 26-10-2021
17th AGM – 27-09-2021
Postal Ballot Notice dated 07-10-2020
16th AGM – 14-09-2020
15th AGM – 26-08-2019
14th AGM – 17-09-2018
Financial Year Q1 Q2 Q3 Q4
2023-24
2022-23
2021-22
2020-21
2019-20
2018-19
2017-18
RTP HY1 HY2
FY 2022-23
FY 2021-22
FY 2020-21
FY 2019-20
FY 2018-19

 

  • Dr. Vikram Shah – Chairman & Managing Director, Shalby Limited at Edelweiss India Conference (Feb’18):

 

  • Dr. Vikram Shah – Chairman & Managing Director, Shalby Limited at IIFL Enterprising India IX-2018 (Feb’18):

  • A Special Episode in CNBC Awaaz – Incredible Journey – Rising stars

 

Financial Year Q1 Q2 Q3 Q4
2019-20
2018-19
2017-18
SHALBY HOSPITAL
Corporate Office :

B-301/302,Mondeal Heights,
S. G. Highway,
Ahmedabad 380015,
Gujarat , India

We're Socially Active!

SHALBY GROUP
Subscribe To Newsletter

© 2024 Shalby Hospitals , Inc. All rights reserved